Dark

CORT
Corcept Therapeutics Inc.
stock NASDAQ

At Close

Mar 30, 2026 3:59:59 PM EDT

38.10USD+1.343%(+0.50)1,955,063

0.00Bid 0.00Ask 0.00Spread

Pre-market

Mar 30, 2026 9:25:30 AM EDT

39.00USD+3.723%(+1.40)5,997

After-hours

Mar 30, 2026 4:31:30 PM EDT

38.12USD+0.039%(+0.02)17,560

OverviewOptionsHistoricalExchangesShortsNews

Jan 28, 2022

10:17AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2022 Benzinga

08:09AM EST Truist Securities Initiates Coverage On Corcept Therapeutics with Buy Rating, Announces Price Target of $30 Benzinga

Jan 23, 2022

01:20PM EST Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ:CORT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Dec 27, 2021

09:00PM EST Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) on behalf of Corcept stockholders. Our investigation concerns whether Corcept has violated the federal securities laws and/or engaged in other unlawful business practices. GlobeNewswire Inc

Dec 20, 2021

04:08PM EST Corcept Therapeutics Reports 10M Share Tender Offer Between $20.75-$23.75/Share In Cash Benzinga

04:05PM EST Corcept Therapeutics Announces Final Results of Previously GlobeNewswire Inc

Dec 16, 2021

08:25AM EST Corcept Therapeutics Reports Prelim. Results Of Previously-Announced Tender Offer For Up To 10M Shares Of Co. Stock Between $20.75-$23.75/Share In Cash Benzinga

08:00AM EST Corcept Therapeutics Announces Preliminary Results of Previously GlobeNewswire Inc

Dec 15, 2021

08:20AM EST Corcept Therapeutics Announces Waiver Of Condition To Its Tender Offer For Common Shares Benzinga

08:00AM EST Corcept Therapeutics Announces Waiver of Condition to its Tender GlobeNewswire Inc

Dec 8, 2021

08:00AM EST Corcept Therapeutics Announces Extension of Previously Announced GlobeNewswire Inc

Nov 10, 2021

08:30AM EST Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today announced that the company will present at the following investor conferences: GlobeNewswire Inc

Nov 8, 2021

08:35AM EST Corcept Therapeutics Reports Commencement Of Tender Offer To Buy Up To 10M Shares Of Common Stock Between $20.75-$23.75/Share Benzinga

08:30AM EST Corcept Therapeutics Announces Commencement of Tender GlobeNewswire Inc

Nov 3, 2021

06:21PM EDT Corcept Therapeutics Q3 Adj. EPS $0.30 Beats $0.20 Estimate, Sales $96.10M Miss $97.19M Estimate Benzinga

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 27, 2021

04:05PM EDT Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). GlobeNewswire Inc

Sep 17, 2021

09:32AM EDT Corcept Therapeutics Inc. (CORT) said that results from its 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer were featured in a proffered paper oral presentation at the European Society for Medical Oncology Congress 2021. RTTNews

08:48AM EDT Corcept Presents Positive Results From Phase 2 Trial Of Relacorilant On Ovarian Cancer RTTNews

08:31AM EDT Corcept Therapeutics Says Results Presented At ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant In Patients With Recurrent Platinum-Resistant Ovarian Cancer Benzinga

08:30AM EDT -- Data from Corcepts 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021 -- Results show statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcepts proprietary selective cortisol modulator, relacorilant GlobeNewswire Inc

Sep 12, 2021

04:04PM EDT The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs Benzinga

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 9, 2021

04:21PM EDT Corcept Announces Presentation Of Results From Randomized Controlled Phase 2 Trial Of Relacorilant In Patients With Recurrent Platinum-Resistant Ovarian Cancer At ESMO 2021 Benzinga

04:05PM EDT -- Data from Corcepts 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021 -- Results show benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcepts proprietary selective cortisol modulator, relacorilant GlobeNewswire Inc

Aug 31, 2021

07:55AM EDT Corcept Therapeutics Granted U.S. Patent #11,103,514 'Treatment of muscular dystrophy' Benzinga

Jul 29, 2021

04:34PM EDT Corcept Therapeutics Q2 Adj. EPS $0.30 Down From $0.32 YoY, Sales $91.60M Up From $88.56M YoY; Reaffirms FY21 Sales Guidance $355M-$385M vs $370.7M Est. Benzinga

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 22, 2021

04:05PM EDT Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). GlobeNewswire Inc

Jul 12, 2021

08:30AM EDT Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced that Amy Flood has joined the company as Chief Human Resources and Communications Officer. GlobeNewswire Inc

Jun 23, 2021

06:15AM EDT HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $29 Benzinga

Jun 22, 2021

10:36AM EDT Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer Benzinga

09:18AM EDT Corcept's Relacorilantfails To Show RTTNews

08:37AM EDT Corcept Therapeutics Reports Preliminary Results From RELIANT Trial; Stops Enrollment RTTNews

08:32AM EDT Corcept Therapeutics Stops Enrollment In RELIANT Trial; Says 'the apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer' Benzinga

08:30AM EDT Preliminary Results From RELIANT Trial of Relacorilant Plus GlobeNewswire Inc

Jun 16, 2021

05:36AM EDT Corcept Therapeutics Director Leonard Baker Reported Purchase of 150,000 Shares @ Avg Price of $21.53/Share in Form 4 Filing on Tuesday Benzinga

Jun 15, 2021

08:30AM EDT Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical GlobeNewswire Inc

Jun 10, 2021

07:34AM EDT Corcept Therapeutics Appoints Joshua Murray To Board RTTNews

07:30AM EDT Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the companys Board of Directors. GlobeNewswire Inc

May 7, 2021

06:56AM EDT Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients Benzinga

May 6, 2021

05:15PM EDT Corcept Therapeutics Sees FY21 Sales $355M-$385M vs $396.2M Est. Benzinga

05:14PM EDT Corcept Therapeutics Q1 Adj. EPS $0.20 Misses $0.21 Estimate, Sales $79.40M Miss $91.81M Estimate Benzinga

04:22PM EDT Corcept Therapeutics Announces Positive Results From Its 178-Patient, Controlled, Phase 2 Trial Of Relacorilant Plus Nab-paclitaxel In Patients With Recurrent Platinum-resistant Ovarian Cancer Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Mar 15, 2021

07:30AM EDT Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab in Patients with Adrenal Cancer with Cortisol Excess Benzinga

07:30AM EDT Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus GlobeNewswire Inc

Mar 1, 2021

04:23PM EST Corcept Therapeutics Names Atabak Mokari As CFO Benzinga

04:05PM EST Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins GlobeNewswire Inc

Feb 23, 2021

04:16PM EST Corcept Therapeutics Reiterates FY21 Sales Guidance Of $375M-$405M Vs. $398.27M Est. Benzinga

04:15PM EST Corcept Therapeutics Q4 EPS $0.27 Beats $0.19 Estimate, Sales $85.70M Miss $87.77M Estimate Benzinga

04:05PM EST Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

12:04PM EST Corcept Therapeutics shares were trading lower after the company reported preliminary Q4 sales results and issued FY21 sales guidance. Benzinga

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 8, 2021

04:17PM EST Corcept Therapeutics Sees FY21 Sales $375M-$405M Vs. $403.17M Est.; Reports Q4 Prelim Sales of $85.7M Down From $87.9M YoY Benzinga

04:05PM EST Corcept Therapeutics Announces Fourth GlobeNewswire Inc

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 1, 2021

04:05PM EST Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021. The company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). GlobeNewswire Inc

Jan 29, 2021

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 18, 2020

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Nov 27, 2020

10:02AM EST Biggest Price Target Changes For Friday Benzinga

06:03AM EST HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $32 Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 23, 2020

05:00PM EST Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the companys Board of Directors. GlobeNewswire Inc

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

12:06PM EST Why Corcept's Stock Is Trading Higher Today Benzinga

05:53AM EST What's moving these stocks in the pre-market hours today? RTTNews

Nov 18, 2020

05:43PM EST U.S. Patent Trial And Appeals Board Affirms Validity Of All Claims Of Corcept's U.S. Patent No.10,195,214, 'Concomitant Administration Of Glucocorticoid Receptor Modulators And CYP3A Inhibitors' Benzinga

05:40PM EST U.S. Patent Trial and Appeals Board Affirms Validity of All Claims GlobeNewswire Inc

04:16PM EST UPDATE: US Patent Trademark Office Doc On Teva v. Corcept Shows Determination 'there was a reasonable likelihood that Petitioner would prevail in showingthat at least' Benzinga

04:15PM EST Traders Circulate Nov. 18 Dated USPTO Court Document On Teva v Corcept (Link To Document) Benzinga

Nov 4, 2020

08:00AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

06:09AM EST HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $22 Benzinga

Nov 3, 2020

04:30PM EST Corcept Therapeutics: Q3 Earnings Insights Benzinga

04:07PM EST Corcept Therapeutics Q3 EPS $0.24 Beats $0.20 Estimate, Sales $86.30M Miss $90.87M Estimate Benzinga

04:05PM EST Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended September30, 2020. GlobeNewswire Inc

04:07AM EST Earnings Scheduled For November 3, 2020 Benzinga

Oct 27, 2020

04:05PM EDT Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2020. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). GlobeNewswire Inc

Oct 15, 2020

10:52AM EDT Patent Lawyer, Daniel Ravicher, Comments On Recent Corcept Patent Challenge Oral Argument From Sept., Says Following Transcript Of Hearing Last Week, 'Argument Went Well' Benzinga

Sep 29, 2020

09:03AM EDT Corcept Therapeutics Incorporated (CORT) and Encourages Long-Term CORT Stockholders to Contact the Firm PR Newswire

Sep 10, 2020

08:42AM EDT Corcept Therapeutics Begins Second Phase 2 Trial Of Miricorilant To Treat Weight Gain Caused By Antipsychotic Medication RTTNews

08:35AM EDT Corcept Therapeutics Initiates Second Phase 2 Trial Of Miricorilant To Treat Weight Gain Caused By Antipsychotic Medication Benzinga

08:30AM EDT Corcept Therapeutics Initiates Second Phase 2 Trial of GlobeNewswire Inc

Sep 3, 2020

09:51AM EDT Looking Into Corcept Therapeutics's Return On Capital Employed Benzinga

08:00AM EDT Benzinga Pro's Top 5 Stocks To Watch For Thursday, Sept. 3, 2020: DKNG, AKBA, CORT, NNVC, SWBI Benzinga

Sep 2, 2020

01:40PM EDT Corcept Therapeutics Shares Up ~53% For Session; Seeing Talk Of Some Patent Validity On Korlym Benzinga

Aug 5, 2020

05:56PM EDT Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc. Business Wire

09:32AM EDT Benzinga's Top Upgrades, Downgrades For August 5, 2020 Benzinga

06:48AM EDT Jefferies Downgrades Corcept Therapeutics to Hold, Announces $16 Price Target Benzinga

Aug 4, 2020

04:46PM EDT Corcept Therapeutics Q2 EPS $0.32 Beats $0.22 Estimate, Sales $88.60M Miss $90.14M Estimate Benzinga

04:06PM EDT Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended June30, 2020. GlobeNewswire Inc

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 28, 2020

04:05PM EDT Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). GlobeNewswire Inc

08:40AM EDT Corcept Therapeutics Enrolls First Patient In GRADIENT Phase 3 Trial Of Relacorilant RTTNews

08:31AM EDT Corcept Therapeutics Initiates Phase 3 Trial Of Relacorilant In Patients With Cushing's Syndrome Of Adrenal Origin Benzinga

08:30AM EDT Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in GlobeNewswire Inc

Jul 23, 2020

08:40AM EDT Corcept Therapeutics Completes Enrollment In Controlled, Phase 2 Trial Of Relacorilant Plus Nab-Paclitaxel In Patients With Metastatic Ovarian Cancer Benzinga

08:30AM EDT Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 GlobeNewswire Inc